This site is intended for health professionals only
Friday 24 November 2017
LatestNews
Share |

Latest News

Adalimumab biosimilar approved in Europe for the treatment of multiple chronic inflammatory diseases

Friday 17th November 2017

Boehringer Ingelheim has announced that the European Commission has granted marketing authorisation for Cyltezo® a biosimilar to Humira® for the treatment of multiple chronic inflammatory diseases in adults and children.

Cyltezo® is the first biosimilar from Boehringer Ingelheim approved in Europe, and marks a significant step forward for us in offering effective, and more affordable treatment options for...

Fri, 17 Nov 2017
Within the framework of the Innovative Medicines Initiative, EFPIA, EBE and Vaccines Europe are also supporting an extensive framework of European collaborative projects (pharmaceutical industry and academia), which address the challenges of antibiotic resistance
Fri, 17 Nov 2017
Trelegy Ellipta is the first once-daily single inhaler triple therapy to be approved in Europe
Fri, 17 Nov 2017
The Declaration highlights the unintended consequences of the release of increasing amounts of pharmaceuticals into the environment on both human and environmental health
Thu, 16 Nov 2017
Adult-onset Still’s disease and systemic juvenile idiopathic arthritis are rare systemic disorders of auto-inflammatory nature
Thu, 16 Nov 2017
Positive opinion based on five studies demonstrating Nplate reduces rates of bleeding in children with rare blood disorder
Thu, 16 Nov 2017
For patients undergoing an allogeneic haematopoietic stem cell transplant, complications arising from cytomegalovirus infection can be life threatening
Thu, 16 Nov 2017
ABP 215 is being developed as a biosimilar to bevacizumab